| Preface |
|
ix | |
| List of Abbreviations |
|
xi | |
| 1 The History of ZIKV Discovery |
|
1 | (14) |
|
1.1 ZIKV Isolation from Monkeys and Mosquitos |
|
|
1 | (5) |
|
1.2 ZIKV Infection in Humans |
|
|
6 | (1) |
|
1.3 ZIKV Infection Spread to Other Hosts and Regions |
|
|
7 | (2) |
|
1.4 Cross-Paths between ZIKV and Other Flaviviruses |
|
|
9 | (1) |
|
|
|
10 | (5) |
| 2 ZIKV: From Silent to Epidemic |
|
15 | (14) |
|
2.1 Outbreak in Yap Island (2007) |
|
|
15 | (1) |
|
2.2 Outbreak in French Polynesia (2013) |
|
|
16 | (2) |
|
2.3 How Did ZIKV Reach Brazil? |
|
|
18 | (1) |
|
2.4 Outbreak in Brazil (2015) |
|
|
18 | (2) |
|
2.5 ZIKV Spread through South, Central, and North Americas |
|
|
20 | (2) |
|
|
|
22 | (7) |
| 3 ZIKV Transmission and Prevention |
|
29 | (20) |
|
3.1 Modes of Transmission |
|
|
29 | (8) |
|
|
|
37 | (3) |
|
|
|
40 | (9) |
| 4 Association with Guillain-Barre Syndrome and Microcephaly |
|
49 | (20) |
|
4.1 Association with Neurological Disorders |
|
|
49 | (9) |
|
|
|
58 | (11) |
| 5 ZIKV Animal Models |
|
69 | (14) |
|
5.1 Animal Models: Embryonated Hen Eggs |
|
|
69 | (1) |
|
5.2 Animal Models: Landrace Piglet |
|
|
69 | (1) |
|
|
|
70 | (4) |
|
5.4 Animal Model: Nonhuman Primate |
|
|
74 | (4) |
|
|
|
78 | (5) |
| 6 Biology of ZIKV |
|
83 | (48) |
|
6.1 Structural and Physical Properties of ZIKV Virion |
|
|
84 | (3) |
|
|
|
87 | (2) |
|
|
|
89 | (2) |
|
6.4 Translation and Proteolytic Processing |
|
|
91 | (1) |
|
6.5 Features of the Nonstructural Proteins |
|
|
92 | (8) |
|
|
|
100 | (4) |
|
6.7 Features of the Structural Proteins |
|
|
104 | (3) |
|
6.8 Virus Assembly and Release from Virus-Infected Cells |
|
|
107 | (2) |
|
|
|
109 | (22) |
| 7 Zika Virus (ZIKV) Strains and Lineages |
|
131 | (16) |
|
7.1 East and West African Lineage |
|
|
131 | (1) |
|
7.2 Africa vs. Asian/American Lineage |
|
|
132 | (8) |
|
|
|
140 | (7) |
| 8 ZIKV-Host Interactions |
|
147 | (32) |
|
8.1 Systematic Studies to Identify ZIKV Affected Functions and Pathways |
|
|
147 | (3) |
|
8.2 Induction and Dysregulation of Innate Immune Responses during ZIKV Infection |
|
|
150 | (6) |
|
8.3 Induction of Cell Death and Apoptosis by ZIKV |
|
|
156 | (4) |
|
8.4 Induction of Autophagy by ZIKV |
|
|
160 | (3) |
|
8.5 Dysregulation of Cell Cycle and Induction of Abnormal Mitosis by ZIKV |
|
|
163 | (1) |
|
|
|
164 | (15) |
| 9 Inhibitors of ZIKV Replication and Infection |
|
179 | (50) |
|
9.1 Drugs That Lead to the Destruction of ZIKV Virions |
|
|
179 | (1) |
|
9.2 Drugs That Inhibit ZIKV Entry and Endocytosis |
|
|
180 | (6) |
|
9.3 Drugs That Target ZIKV NS2B-NS3 Protease Activity |
|
|
186 | (5) |
|
9.4 Drugs That Target ZIKV NS5 RNA-Dependent RNA Polymerase Activity |
|
|
191 | (9) |
|
9.5 Neutralizing Antibodies That Target ZIKV Structural Protein |
|
|
200 | (1) |
|
9.6 Drugs That Inhibit ZIKV Infection by Targeting Host Machinery |
|
|
201 | (4) |
|
9.7 Drugs That Show Neuroprotective Activity but Do Not Suppress ZIKV Replication: Emricasan |
|
|
205 | (1) |
|
9.8 Other Drugs That Inhibit ZIKV Infection Identified from a Screening of FDA-Approved Drugs |
|
|
206 | (4) |
|
|
|
210 | (19) |
| 10 Long-Term Care and Perspectives |
|
229 | (8) |
|
10.1 Prenatal Care and Diagnosis of Abnormal Fetus Development |
|
|
229 | (1) |
|
10.2 Long-Term Care for Patients Affected by ZIKV |
|
|
230 | (1) |
|
10.3 Assistance to Families with Children Affected by ZIKV |
|
|
230 | (1) |
|
|
|
231 | (1) |
|
|
|
232 | (5) |
| Index |
|
237 | |
